Calidi Biotherapeutics (CLDI) Shares Outstanding (Weighted Average) (2021 - 2025)
Calidi Biotherapeutics' quarterly Shares Outstanding (Weighted Average) came in at $2569.0 in Q2 2025, up 478.6% year-on-year from $444.0 in Q2 2024, and down 90.52% quarter-over-quarter from $27086.0 in Q1 2025.
Calidi Biotherapeutics has reported Shares Outstanding (Weighted Average) for 5 years, with the latest figure at $2569.0 in Q2 2025.
- For the quarter ending Q2 2025, Shares Outstanding (Weighted Average) rose 478.6% year-over-year to $2569.0; the trailing twelve-month figure through Jun 2025 stood at $2569.0 (up 478.6% YoY), and the FY2024 full-year result was $2.0 million, up 21.59% from the prior year.
- Shares Outstanding (Weighted Average) for Q2 2025 stood at $2569.0, down from $27086.0 in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $8.7 million in Q1 2023, with the low at $444.0 in Q2 2024.
- Average Shares Outstanding (Weighted Average) over 5 years is $3.1 million, with a median of $1.4 million recorded in 2023.
- Year-over-year, Shares Outstanding (Weighted Average) plunged 99.96% in 2024 and soared 661.91% in 2025.
- Tracing CLDI's Shares Outstanding (Weighted Average) over 5 years: stood at $5.8 million in 2021, then jumped by 47.91% to $8.5 million in 2022, then slumped by 80.18% to $1.7 million in 2023, then sank by 99.96% to $667.0 in 2024, then surged by 285.16% to $2569.0 in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $2569.0 (Q2 2025), $27086.0 (Q1 2025), and $667.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 104.00 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | 16.04 Bn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2,569.00 |
| Mar 31, 2025 | 27,086.00 |
| Dec 31, 2024 | 667.00 |
| Sep 30, 2024 | 652.00 |
| Jun 30, 2024 | 444.00 |
| Mar 31, 2024 | 3,555.00 |
| Dec 31, 2023 | 1.69 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | 872,000.00 |
| Mar 31, 2023 | 8.66 Mn |
| Dec 31, 2022 | 8.51 Mn |
| Sep 30, 2022 | 8.48 Mn |
| Jun 30, 2022 | 5.75 Mn |
| Mar 31, 2022 | 5.75 Mn |
| Dec 31, 2021 | 5.75 Mn |